BACKGROUND Prognosis of recurrent or metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil …

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …

Background Until the emergence of immune checkpoint inhibitors, the EXTREME regimen
comprising platinum-based chemotherapy plus cetuximab was the standard of care for …

Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide.
However, identifying the optimal treatment for recurrent or metastatic head and neck cancer …

Background The EXTREME protocol is the standard of care for recurrent or metastatic head
and neck squamous-cell carcinoma (R/M HNSCC) in first line. Beyond the first-line except …

BACKGROUND The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …

Background Little is known regarding the association of cetuximab treatment beyond
progression (TBP) with survival among patients with recurrent or metastatic head and neck …

Background: The EXTREME regimen (cetuximab+ PBT≤ 6 cycles followed by cetuximab-
alone maintenance until progressive disease [PD]) was the first treatment in 30 years to …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …